Latest Genmab Stories
LONDON and COPENHAGEN, Denmark, July 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE and LSE: GSK) and Genmab A/S (OMX: GEN) announced today an amendment to the ofatumumab co-development and commercialisation agreement.
PHILADELPHIA, April 29 /PRNewswire/ -- TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute (NCI) to conduct an investigator sponsored Phase II clinical trial. For this study, the NCI's Surgery Branch Chief, Dr. Steven A.
PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4Â®) from Genmab A/S (OMX: GEN).
SCOTTSDALE, Ariz., Jan. 15 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies.
SCOTTSDALE, Ariz., Nov.
NEW YORK, Nov.
NEW YORK, Oct.
NEW YORK, Oct.
ORLANDO, Fla., May 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: GEN] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to three that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab.
US drug regulators are carefully scrutinizing a new leukemia drug from pharmaceutical giant GlaxoSmithKline PLC and Genmab to determine whether the medication offers patients enough benefit to sanction its approval.
- A volcanic mudflow.